SAILIFE

Sai Life Science Share Price

 

 

Invest in Sai Life Science with 3.13X leverage

Invest with MTF

Performance

  • Low
  • ₹906
  • High
  • ₹928
  • 52 Week Low
  • ₹636
  • 52 Week High
  • ₹983
  • Open Price₹920
  • Previous Close₹915
  • Volume187,121
  • 50 DMA₹878.48
  • 100 DMA₹871.93
  • 200 DMA₹833.60

Investment Returns

  • Over 1 Month + 2.08%
  • Over 3 Month + 5.98%
  • Over 6 Month + 4.11%
  • Over 1 Year + 39.55%

Smart Investing Starts Here Start SIP with Sai Life Science for Steady Growth!

Invest Now

Sai Life Science Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 58.7
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 19,557
  • P/B Ratio
  • 8.6
  • Average True Range
  • 38.84
  • EPS
  • 16.06
  • Dividend Yield
  • 0
  • MACD Signal
  • -3.49
  • RSI
  • 56.39
  • MFI
  • 73.32

Sai Life Science Financials

Sai Life Science Technicals

EMA & SMA

Current Price
₹924.10
+ 9.25 (1.01%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹878.49
  • 50 Day
  • ₹878.48
  • 100 Day
  • ₹871.93
  • 200 Day
  • ₹833.60

Resistance and Support

912.12 Pivot Speed
  • R3 986.23
  • R2 960.62
  • R1 937.73
  • S1 889.23
  • S2 863.62
  • S3 840.73

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sai Life Sciences, a leading CRDMO, partners with 280+ global pharma and biotech companies to accelerate NCE small molecule programs. across India, UK, USA, and Japan, it ensures quality and compliance through USFDA-certified facilities.

Sai Life Sciences Ltd has an operating revenue of Rs. 2,169.86 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 13% is healthy, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 8% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around -2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 99 which is a GREAT score indicating consistency in earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of A is the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sai Life Science Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-05 Quarterly Results
2025-11-06 Quarterly Results
2025-08-07 Quarterly Results
2025-05-13 Audited Results
2025-02-06 Quarterly Results

Sai Life Science F&O

Sai Life Science Shareholding Pattern

34.7%
27.57%
3.24%
21.41%
5.94%
7.14%

About Sai Life Science

  • NSE Symbol
  • SAILIFE
  • BSE Symbol
  • 544306
  • Managing Director & CEO
  • Mr. Krishnam Raju Kanumuri
  • ISIN
  • INE570L01029

Similar Stocks to Sai Life Science

Sai Life Science FAQs

Sai Life Science share price is ₹924 As on 16 February, 2026 | 11:09

The Market Cap of Sai Life Science is ₹19556.6 Cr As on 16 February, 2026 | 11:09

The P/E ratio of Sai Life Science is 58.7 As on 16 February, 2026 | 11:09

The PB ratio of Sai Life Science is 8.6 As on 16 February, 2026 | 11:09

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23